Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration
XTalks
AUGUST 30, 2022
A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?
83 
Let's personalize your content